CN Patent

CN120757605A — 抗冠状病毒化合物及其组合物和用途

Assigned to Shanghai Kejun Pharmaceutical Technology Co ltd · Expires 2025-10-10 · 1y expired

What this patent protects

本公开涉及在抑制3‑胰凝乳蛋白酶样蛋白酶中表现出活性的化合物，以及包含这些化合物的药物组合物和通过施用这些化合物或药物组合物来治疗病毒感染的方法。

USPTO Abstract

本公开涉及在抑制3‑胰凝乳蛋白酶样蛋白酶中表现出活性的化合物，以及包含这些化合物的药物组合物和通过施用这些化合物或药物组合物来治疗病毒感染的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120757605A
Jurisdiction
CN
Classification
—
Expires
2025-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Kejun Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.